Skip to main content
Clinical Trials/NCT03120637
NCT03120637
Completed
Phase 4

Evaluating in Cirrhotics With Refractory Vasoplegia the Effect of Methylene Blue in Sepsis: A Randomized Controlled Trial

Institute of Liver and Biliary Sciences, India1 site in 1 country111 target enrollmentJanuary 1, 2017

Overview

Phase
Phase 4
Intervention
Methylene Blue
Conditions
Septic Shock
Sponsor
Institute of Liver and Biliary Sciences, India
Enrollment
111
Locations
1
Primary Endpoint
Survival in both groups
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

Mortality rates associated septic shock remains unacceptably high, around 20-50%, with refractory hypotension in half of these patients. Widespread vasodilatation involves the activation of the soluble intracellular enzyme guanylate cyclase (GC) by nitric oxide (NO), resulting in the production of cyclic guanosine monophosphate (cGMP). Initially discovered as an endothelium-derived relaxing factor in blood vessels, NO is made by the enzyme nitric oxide synthase (NOS). It has been suggested that the inhibition of NO generation might be a treatment option for sepsis and septic shock. Methylene blue (MB) is a dye that easily crosses cell membranes, inhibits iNOS, and is capable of inhibiting the GC enzyme in vascular smooth muscle cells.Early use of MB can block the progressive decrease in systemic vascular resistance of patients unresponsive to noradrenaline and mitigate the need for prolonged vasoconstrictor use. The investigators propose to study the effect of methylene blue on cirrhotic adults with sepsis, with refractory vasoplegia unresponsive to maximum doses of noradrenaline and vasopressin.

Registry
clinicaltrials.gov
Start Date
January 1, 2017
End Date
January 10, 2018
Last Updated
8 years ago
Study Type
Interventional
Study Design
Sequential
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adult patients (\>18 years )
  • Refractory septic shock (Noradrenaline \>0.5mcg/kg/mt )

Exclusion Criteria

  • Declined consent
  • Less than 18 years old
  • Immunosuppressant patients (e.g. on steroid medication, active anti-cancer chemotherapeutic agent, etc.)
  • Glucose-6-phosphate dehydrogenase deficiency
  • Medication of Serotonin modulator/SSRI
  • Pre-existing Pulmonary Hypertension
  • CKD-Stage IV/V
  • Patients with GI bleed
  • Patients on DNR
  • Patients declared Brain dead

Arms & Interventions

Methylene Blue

Methylene Blue intravenous route, 2 mg/kg Loading Dose over 30 minutes, followed by 0.5 mg/kg/hr for 6 hours

Intervention: Methylene Blue

Outcomes

Primary Outcomes

Survival in both groups

Time Frame: 2 days

Secondary Outcomes

  • Systemic Vascular Resistance(6 hours)
  • Mean Arterial Pressure(6 hours)
  • Decrease of vasopressor dose of 20 percent from time of start of test drug.(6 hours)

Study Sites (1)

Loading locations...

Similar Trials